PTSM: Pharmaceutical Technology Sourcing and Management, Jul 12, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Jul 12, 2011
APIs
SOCMA Focuses on Concerns of Batch and Custom Manufacturers
By Patricia Van Arnum
SOCMA President and CEO Lawrence D. Sloan discusses the key policy initiatives and activities of the association.
Tracking Pharmaceutical and API Growth in China
By Patricia Van Arnum
Strong growth is projected for the pharmaceutical industry in China, offering opportunities for drug companies and manufacturers of active pharmaceutical ingredients.
Outsourcing
Wanted: Better Upstream Bioprocessing Technologies
By Eric Langer
A recent industry survey shows keen interest in improving bioreactors and cell-culture media.
Pharma Partner Focus
Almac Expands in North America
By Patricia Van Arnum
With a new North American headquarters and expanded operations, Almac is furthering its transatlantic approach to contract development and manufacturing.
CSR and Sustainability Forum
Pharma Industry Prepares for UN High-Level Meeting on Noncommunicable Diseases
The International Federation of Pharmaceutical Manufacturers and Associations issues a Framework for Action for noncommunicable diseases.
Sustainability at Work: Solar Energy
By Erik Greb
New Age Industries, a manufacturer of plastic molding and fittings for the pharmaceutical and biopharmaceutical industries, implements a solar-energy project at its Pennsylvania facility.
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here